

Joint Symposium 6

Cardiovascular Committee / American Society of Nuclear Cardiology (ASNC)

Friday, October 23, 09:00-10:30

Session Title

Detecting Cardiac Toxicity of Cancer Therapies with Nuclear Imaging

Chairperson

Fabien Hyafil (Paris, France)

Programme

09:00 - 09:22 Jutta Bergler-Klein (Vienna, Austria): Cardiac Complications of Cancer Therapy - A Clinical Perspective

09:22 - 09:44 Raymond Russell (Providence, United States of America / ASNC): Assessing LV Dysfunction

09:44 - 10:06 Christop Rischpler (Essen, Germany): Detecting Myocardial Injury

10:06 - 10:28 Sharmila Dorbala (Boston, United States of America / ASNC): Perspectives for CV Imaging in Cardio-Oncology

Educational Objectives

1. Review the toxic effects of oncological treatments on the heart.
2. Discuss the role of nuclear imaging to identify cardiac toxicity of oncological treatments.
3. Open perspectives on the role of multi-modality imaging for the early identification of cardiac toxicity of oncological treatments.

Summary

Cardio-oncology is a growing field focused on the prevention and treatment of cardiovascular disease in oncologic patients. While a major focus of chemotherapy-related cardiac toxicity has been on left ventricular ejection fraction, oncologic treatment can lead to several other cardiovascular lesions. In this session, we will review the toxic effects of oncological treatments on the heart, summarize the role of nuclear cardiology in the monitoring of LVEF and identifying early cardiac lesions induced by these treatments, and discuss the role of multi-modality imaging in cardio-oncology.

Key Words

Cardiac imaging, Oncology, Toxicity, LV dysfunction